Bacteria: Gram-negative

Klebsiella oxytoca

General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.

Overview

A Klebsiella species found in the gut and the healthcare environment.

Infections

Healthcare-associated urinary, respiratory and bloodstream infection; antibiotic-associated hemorrhagic colitis (toxin-producing strains).

Signs and symptoms

Urinary infection: painful urination, frequency, urgency, flank pain or fever. Wound infection: redness, swelling, warmth and drainage. Bloodstream infection: fever, chills and low blood pressure. Antibiotic-associated hemorrhagic colitis: sudden bloody diarrhea and cramping, typically during or after a course of penicillin-type antibiotics.

Antibiotic and antimicrobial resistance

Chromosomal beta-lactamase; may acquire ESBL (ESBL genes) or carbapenemase genes (carbapenemases).

Treatment considerations

Guided by susceptibility testing; K. oxytoca is intrinsically resistant to ampicillin. Antibiotic-associated hemorrhagic colitis usually resolves once the causative antibiotic is stopped.

Klebsiella oxytoca culture on an agar plate
Klebsiella oxytoca culture (NRRL B-199). USDA ARS Culture Collection; public domain. Image source
Gram-negative rods, schematic
Gram-negative rods. Schematic, not to scale; InnovexLab.

Sources

  1. CDC. Klebsiella.
  2. CDC. Healthcare-associated infections: diseases and organisms.
  3. CDC. ESBL-producing Enterobacterales.
  4. CDC. Carbapenem-resistant Enterobacterales (CRE).
  5. IDSA. Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
  6. IDSA. Complicated Urinary Tract Infections guideline.

Sources accessed November 2026. Links open external sites that InnovexLab does not control.

Medical disclaimer

This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.

Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.

Sources, image credits and editorial policy

Discuss a testing program with InnovexLab

Review the panel that fits your patients, its specimen requirements, and how results and billing work.